COVID-19 and pregnancy: clinical outcomes; mechanisms, and vaccine efficacy

Kumar, Deepak; Verma, Seema; Mysorekar, Indira U.

doi:10.1016/j.trsl.2022.08.007

Cited by 25 publications

(26 citation statements)

References 222 publications

(210 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased sFlt-1/PlGF ratio or decreased PlGF values have been associated to adverse maternal and perinatal outcomes. [3] , [13] , [24] , [25] , [26] Studies indicate that COVID-19 in pregnancy can induce higher incidence of adverse perinatal outcomes, as well as PE-like syndrome. [24] , [25] , [26] The same studies suggest that the biomarkers testing (such as PlGF and sFlt-1/PlGF ratio) could be used to differentiate PE from severe COVID-19 and improve clinical management.…”

Section: Discussionmentioning

confidence: 99%

“…During the COVID-19 pandemic, these populations have also been disproportionately affected by severe infections due to delays in healthcare, difficulties in testing and managing the disease, restricted availability of intensive care units, and inadequate management of complications, all aggravated by low access to vaccination. Outcomes are particularly striking for COVID-19 infections during pregnancy and postpartum, with increased numbers reported for maternal morbidity and mortality not only due to the challenges with healthcare, but also because of pregnancy itself as a risk factor for severe disease[ [3] , [4] , [5] ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of biomarkers (sFlt-1/PlGF) in cases of COVID-19 for distinguishing preeclampsia and guiding clinical management

Nobrega

Guida

Novaes

et al. 2023

Pregnancy Hypertension

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Role of biomarkers (sFlt-1/PlGF) in cases of COVID-19 for distinguishing preeclampsia and guiding clinical management

Nobrega

Guida

Novaes

et al. 2023

Pregnancy Hypertension

View full text Add to dashboard Cite

“…A higher risk of adverse outcomes in pregnant women with either Plasmodium spp. [ 23 ] or SARS-CoV-2 [ 24 , 25 ] have been reported, but not so much for co-infected pregnant women, including co-infection with P. vivax [ 7 , 15 ] and Plasmodium ovale [ 6 ]. No similar reports for P. falciparum co-infection were found.…”

Section: Discussionmentioning

confidence: 99%

“…SARS-CoV-2 mono-infection during pregnancy is also associated with an increased risk of pre-eclampsia, preterm birth, low birth weight, stillbirth, and mechanical ventilation [ 27 , 28 ]. Severe placentitis and vascular dysfunction have been described, leading to long-term multisystemic defects in exposed infants [ 24 ]. Thus, delayed care may have life-threatening consequences [ 15 ], as was evident in three of the five patients of this case series.…”

Section: Discussionmentioning

confidence: 99%

Plasmodium vivax and SARS-CoV-2 co-infection in Venezuelan pregnant women: a case series

Carrión‐Nessi

Mendoza-Millán

Omaña‐Ávila

et al. 2023

Malar J

View full text Add to dashboard Cite

Background Malaria‐endemic areas are not spared from the impact of coronavirus disease 2019 (COVID-19), leading to co-infection scenarios where overlapping symptoms impose serious diagnostic challenges. Current knowledge on Plasmodium spp. and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co‐infection in pregnant women remains limited, especially in Latin America, where Plasmodium vivax infection is highly prevalent. Methods This is a case series of five pregnant women with P. vivax and SARS-CoV-2 co-infection hospitalized in two main malaria referral centers of the Capital District and Bolivar state, Venezuela between March 13, 2020 and December 31, 2021. Results Clinical and laboratory data from five pregnant women with a mean age of 22 years were analyzed; three of them were in the third trimester of pregnancy. Comorbidities included obesity in two cases, hypertension in one, and asthma in one. Three out of five patients had severe to critical COVID-19 disease. Dry cough, fever, chills, and headache were the most frequent symptoms reported. Laboratory analyses showed elevated aspartate/alanine aminotransferase and creatinine levels, thrombocytopenia, and severe anemia as the most relevant abnormalities. The mean period between symptom onset and a positive molecular test for SARS-CoV-2 infection or positive microscopy for Plasmodium spp. was 4.8 ± 2.5 days and 2.8 ± 1.6 days, respectively. The mean hospital stay was 5.4 ± 7 days. Three women recovered and were discharged from the hospital. Two women died, one from cerebral malaria and one from respiratory failure. Three adverse fetal outcomes were registered, two miscarriages and one stillbirth. Conclusion This study documented a predominance of severe/critical COVID-19 disease and a high proportion of adverse maternal–fetal outcomes among pregnant women with malaria and COVID-19 co-infection. More comprehensive prospective cohort studies are warranted to explore the risk factors, management challenges, and clinical outcomes of pregnant women with this co-infection.

show abstract

“…In the past, many infectious viruses have emerged and re-emerged, with some becoming a global threat to public health (42, 43) e.g., the ongoing pandemic of COVID-19 (44, 45). At the same time, other infectious viruses exist for long periods.…”

Section: Discussionmentioning

confidence: 99%

Discovery And Characterization of Small Molecule Inhibitors of Zika Virus Replication

Kumar

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Zika virus (ZIKV) is a flavivirus, and ZIKV infections in the past 15 years have been linked to Guillain-Barre syndrome and severe complications during pregnancy associated with congenital Zika syndrome. There are no approved therapies or vaccines for ZIKV. In recent years, advances in structure-based drug design methodologies have accelerated drug development pipelines for identifying promising inhibitory compounds against viral diseases. Among ZIKV proteins, NS2B-NS3 protease is an attractive target for antiviral drug development due to its vital role in the proteolytic processing of the single polyprotein. To find potential inhibitors against ZIKV, we used molecular docking at the NS2B-NS3 protease active site as a virtual screening approach with small molecules diverse scaffold-based library with rigorous drug-likeness filters. The top-hit compounds with stable molecular dynamics trajectories were then subjected to in-vitro efficacy testing against ZIKV. In docking and molecular dynamics simulation studies, compound F1289-0194 showed stable binding to the NS2B-NS3 protease active site. Furthermore, viral load assays, immunofluorescence, and plaque reduction assays demonstrated that compound F1289-0194 significantly reduced ZIKV load and replication in Vero cells while maintaining cellular integrity. Thus, the compound F1289-0194 merits further investigation as a novel inhibitor against ZIKV replication.

show abstract

COVID-19 and pregnancy: clinical outcomes; mechanisms, and vaccine efficacy

Cited by 25 publications

References 222 publications

Role of biomarkers (sFlt-1/PlGF) in cases of COVID-19 for distinguishing preeclampsia and guiding clinical management

Role of biomarkers (sFlt-1/PlGF) in cases of COVID-19 for distinguishing preeclampsia and guiding clinical management

Plasmodium vivax and SARS-CoV-2 co-infection in Venezuelan pregnant women: a case series

Discovery And Characterization of Small Molecule Inhibitors of Zika Virus Replication

Contact Info

Product

Resources

About